One is using ARV-393, a PROTAC for blood cancers that degrades BCL6, a previously undruggable target. The second involves ARV-102, which degrades a protein relevant to neuroscience. “Our ...
targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information ...
Crabtree and Nathanael Gray, also at Stanford, first unveiled the TCIP modality in 2022, describing a bifunctional molecule that binds BCL6 and BRD4. BCL6 is a transcriptional repressor that ...
We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a ...
targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information ...
The researchers engineered a unique molecular compound that binds together two proteins – BCL6 and CDK9 – to trigger the activation of apoptosis genes in cancer cells. By redirecting an ...
Taken together, our study demonstrated that IL-12 directly activated both STAT1 and STAT4 and regulated BCL6 and TBX21 gene by alteration of histone modifications, resulting in differentiation of ...
LMU researchers have shown that a particular type of immune cell acts more flexibly than previously thought—with the potential for new therapeutic approaches. As the researchers demonstrate ...
NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback